Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | USP1 | O94782 | 1/20 | 0.43 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429794 | 0.88 | NPC1 (0.53) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL5441347 | 0.87 | APP (0.53) | MEN1KMT2ARAB9AAPPMAPT | |
| SCHEMBL5432244 | 0.86 | RAB9A (0.46) | CHRM4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5441336 | 0.85 | NPC1 (0.55) | MEN1KMT2ANPC1RAB9AAPP | |
| SCHEMBL5444802 | 0.84 | ICAM1 (0.48) | CHRM4MEN1KMT2AAPPMAPT | |
| SCHEMBL5430194 | 0.82 | NPY5R (0.46) | MEN1KMT2AAPPMAPTEGFR | |
| SCHEMBL3118967 | 0.81 | TNF (0.48) | CHRM4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5432241 | 0.79 | RAB9A (0.48) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL5429140 | 0.78 | RXFP1 (0.53) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL5425019 | 0.78 | RAB9A (0.50) | NPC1RAB9AAPPMAPTNR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275984-A1 | Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275984-A1 | Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors | GRM2, GRIA2, GRM1 | CHRM4 332/4885MEN1 4364/4885KMT2A 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.